BR112016007816A2 - composições peptídicas inovadoras - Google Patents

composições peptídicas inovadoras

Info

Publication number
BR112016007816A2
BR112016007816A2 BR112016007816A BR112016007816A BR112016007816A2 BR 112016007816 A2 BR112016007816 A2 BR 112016007816A2 BR 112016007816 A BR112016007816 A BR 112016007816A BR 112016007816 A BR112016007816 A BR 112016007816A BR 112016007816 A2 BR112016007816 A2 BR 112016007816A2
Authority
BR
Brazil
Prior art keywords
peptide compositions
innovative
innovative peptide
compositions
things
Prior art date
Application number
BR112016007816A
Other languages
English (en)
Inventor
Franklin Richard
Original Assignee
Tarix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarix Pharmaceuticals Ltd filed Critical Tarix Pharmaceuticals Ltd
Publication of BR112016007816A2 publication Critical patent/BR112016007816A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção fornece, entre outras coisas, peptídeos e composições inovadores para tratar doenças.
BR112016007816A 2013-10-11 2014-10-01 composições peptídicas inovadoras BR112016007816A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361890056P 2013-10-11 2013-10-11
US201461940095P 2014-02-14 2014-02-14
PCT/US2014/058646 WO2015054006A2 (en) 2013-10-11 2014-10-01 Novel peptide compositions

Publications (1)

Publication Number Publication Date
BR112016007816A2 true BR112016007816A2 (pt) 2017-12-05

Family

ID=52813728

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007816A BR112016007816A2 (pt) 2013-10-11 2014-10-01 composições peptídicas inovadoras

Country Status (13)

Country Link
EP (1) EP3054967A4 (pt)
JP (1) JP2017501967A (pt)
KR (1) KR20160065969A (pt)
CN (1) CN105828831A (pt)
AU (1) AU2014332346B2 (pt)
BR (1) BR112016007816A2 (pt)
CA (1) CA2926641A1 (pt)
CL (1) CL2016000836A1 (pt)
IL (1) IL244956B (pt)
MX (1) MX2016004660A (pt)
RU (1) RU2016112931A (pt)
SG (1) SG11201602661PA (pt)
WO (1) WO2015054006A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017150327A1 (ja) * 2016-03-03 2017-09-08 不二製油グループ本社株式会社 神経栄養因子の脳内分泌促進するための食品添加用組成物
SG11201907398TA (en) * 2017-02-16 2019-09-27 Caregen Co Ltd Conjugate of salicylic acid and peptide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
EP0937103B1 (en) 1996-07-12 2007-11-28 McGILL UNIVERSITY Compounds and methods for modulating cell adhesion
WO2001053331A2 (en) 2000-01-24 2001-07-26 Adherex Technologies, Inc. Peptidomimetic modulators of cell adhesion
US7563862B2 (en) * 2001-08-24 2009-07-21 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use in treatment of brain damage
AU2002335657A1 (en) * 2001-08-24 2003-03-10 Neuronz Biosciences, Inc. Neural regeneration peptide and methods for their use in treatment of brain damage
WO2004058807A2 (en) * 2002-12-24 2004-07-15 Algonomics N.V. Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
EP1685151A4 (en) * 2003-10-31 2009-04-22 Neuren Pharmaceuticals Ltd NEURONAL REGENERATION OF PEPTIDES AND METHODS OF USE IN THE TREATMENT OF BRAIN DISORDERS
WO2007011595A2 (en) * 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Neural regeneration peptides and antioxidants protect neurons from degeneration
CA2804618C (en) * 2010-07-09 2020-09-08 Dana-Faber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
CN104394878A (zh) * 2012-02-10 2015-03-04 塔瑞克斯制药有限公司 用于治疗周围血管疾病的组合物和方法

Also Published As

Publication number Publication date
EP3054967A4 (en) 2017-04-19
AU2014332346A1 (en) 2016-05-05
MX2016004660A (es) 2016-11-14
EP3054967A2 (en) 2016-08-17
CA2926641A1 (en) 2015-04-16
WO2015054006A3 (en) 2015-06-04
AU2014332346B2 (en) 2019-01-24
RU2016112931A (ru) 2017-11-16
IL244956A0 (en) 2016-05-31
CL2016000836A1 (es) 2016-09-16
WO2015054006A2 (en) 2015-04-16
IL244956B (en) 2019-10-31
KR20160065969A (ko) 2016-06-09
SG11201602661PA (en) 2016-05-30
RU2016112931A3 (pt) 2018-06-20
CN105828831A (zh) 2016-08-03
JP2017501967A (ja) 2017-01-19

Similar Documents

Publication Publication Date Title
UY36774A (es) Anticuerpos de enlace-tau
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
UY34885A (es) Proteínas de unión anti-mesotelina
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
EA201591137A1 (ru) Ингибиторы mk2 и их применения
NZ725568A (en) Modified j-chain
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
DK3723783T3 (da) Mitokondrie-målrettede peptider
UY36773A (es) Anticuerpos de enlace-tau
EA201790380A1 (ru) Ингибиторы mk2 и их применения
HK1254601A1 (zh) 新型肽
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
ZA201803551B (en) Personal care composition comprising taurine, arginine, glycine
TR201901228T4 (tr) Vortioksetin piroglutamat.
EP3310373A4 (en) STAPLING THIOL-EENE-BASED PEPTIDES AND USES THEREOF
DK3548058T3 (da) Sammensætninger omfattende peptid wkdeagkplvk
IL252902A0 (en) Amino acid and peptide conjugates and their uses
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
AR097668A1 (es) Colorante-polímero
UY35463A (es) Formulaciones de polipéptido fc-factor ix.
EA201791716A1 (ru) Фармацевтический состав
DK3402573T3 (da) Aminosyreholdig sammensætning
KR20180085014A (ko) 펩티드 조성물
BR112016007816A2 (pt) composições peptídicas inovadoras

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements